In clinical trials to date, the safety and tolerability of
duloxetine in the dosage range of 40–120 mg/day
have been assessed. In an 8-month study, the most common treatment-emergent
adverse events included nausea, dry mouth, vomiting, yawning, and
night sweats (Pigott et al. 2007). Most of these emerged
early, within the first 8 weeks. Other studies have reported insomnia,
somnolence, headaches, ejaculation disorders, diarrhea, constipation,
and dizziness as common adverse events with duloxetine (Detke et al. 2002a, 2002b; Khan et al. 2007; Nierenberg et al. 2007).